Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor

Matthias Hofmann, Ralph Pflanzer, Nadja Nicole Zöller, August Bernd, Roland Kaufmann, Diamant Thaci, Jürgen Bereiter-Hahn, Satoshi Hirohata, Stefan Kippenberger

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Characteristically, most solid tumors exhibit an increased tumor interstitial fluid pressure (TIFP) that directly contributes to the lowered uptake of macromolecular therapeutics into the tumor interstitium. Abnormalities in the tumor-associated lymph vessels are a central brick in the development and prolonged sustaining of an increased TIFP. In the current study, vascular endothelial growth factor C (VEGF-C) was used to enhance tumor-associated lymphangiogenesis as a new mechanism to actively reduce the TIFP by increased lymphatic drainage of the tumor tissue. Human A431 epidermoid vulva carcinoma cells were inoculated in NMRI nu/nu mice to generate a xenograft mouse model. Seven days after tumor cell injection, VEGF-C was peritumorally injected to induce lymphangiogenesis. Tumor growth and TIFP was lowered significantly over time in VEGF-C-treated tumors in comparison to control or VEGF-A-treated animals. These data demonstrate for the first time that actively induced lymphangiogenesis can lower the TIFP in a xenograft tumor model and apparently reduce tumor growth. This model represents a novel approach to modulate biomechanical properties of the tumor interstitium enabling a lowering of TIFP in vivo.

Original languageEnglish
Pages (from-to)398-404
Number of pages7
JournalTranslational Oncology
Volume6
Issue number4
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Lymphangiogenesis
Vascular Endothelial Growth Factor C
Extracellular Fluid
Pressure
Neoplasms
Heterografts
Vulva

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hofmann, M., Pflanzer, R., Zöller, N. N., Bernd, A., Kaufmann, R., Thaci, D., ... Kippenberger, S. (2013). Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor. Translational Oncology, 6(4), 398-404. https://doi.org/10.1593/tlo.13274

Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor. / Hofmann, Matthias; Pflanzer, Ralph; Zöller, Nadja Nicole; Bernd, August; Kaufmann, Roland; Thaci, Diamant; Bereiter-Hahn, Jürgen; Hirohata, Satoshi; Kippenberger, Stefan.

In: Translational Oncology, Vol. 6, No. 4, 08.2013, p. 398-404.

Research output: Contribution to journalArticle

Hofmann, M, Pflanzer, R, Zöller, NN, Bernd, A, Kaufmann, R, Thaci, D, Bereiter-Hahn, J, Hirohata, S & Kippenberger, S 2013, 'Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor', Translational Oncology, vol. 6, no. 4, pp. 398-404. https://doi.org/10.1593/tlo.13274
Hofmann, Matthias ; Pflanzer, Ralph ; Zöller, Nadja Nicole ; Bernd, August ; Kaufmann, Roland ; Thaci, Diamant ; Bereiter-Hahn, Jürgen ; Hirohata, Satoshi ; Kippenberger, Stefan. / Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor. In: Translational Oncology. 2013 ; Vol. 6, No. 4. pp. 398-404.
@article{a92ba7ec1f814561a45a8d139a8e5b96,
title = "Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor",
abstract = "Characteristically, most solid tumors exhibit an increased tumor interstitial fluid pressure (TIFP) that directly contributes to the lowered uptake of macromolecular therapeutics into the tumor interstitium. Abnormalities in the tumor-associated lymph vessels are a central brick in the development and prolonged sustaining of an increased TIFP. In the current study, vascular endothelial growth factor C (VEGF-C) was used to enhance tumor-associated lymphangiogenesis as a new mechanism to actively reduce the TIFP by increased lymphatic drainage of the tumor tissue. Human A431 epidermoid vulva carcinoma cells were inoculated in NMRI nu/nu mice to generate a xenograft mouse model. Seven days after tumor cell injection, VEGF-C was peritumorally injected to induce lymphangiogenesis. Tumor growth and TIFP was lowered significantly over time in VEGF-C-treated tumors in comparison to control or VEGF-A-treated animals. These data demonstrate for the first time that actively induced lymphangiogenesis can lower the TIFP in a xenograft tumor model and apparently reduce tumor growth. This model represents a novel approach to modulate biomechanical properties of the tumor interstitium enabling a lowering of TIFP in vivo.",
author = "Matthias Hofmann and Ralph Pflanzer and Z{\"o}ller, {Nadja Nicole} and August Bernd and Roland Kaufmann and Diamant Thaci and J{\"u}rgen Bereiter-Hahn and Satoshi Hirohata and Stefan Kippenberger",
year = "2013",
month = "8",
doi = "10.1593/tlo.13274",
language = "English",
volume = "6",
pages = "398--404",
journal = "Translational Oncology",
issn = "1936-5233",
publisher = "Neoplasia Press",
number = "4",

}

TY - JOUR

T1 - Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor

AU - Hofmann, Matthias

AU - Pflanzer, Ralph

AU - Zöller, Nadja Nicole

AU - Bernd, August

AU - Kaufmann, Roland

AU - Thaci, Diamant

AU - Bereiter-Hahn, Jürgen

AU - Hirohata, Satoshi

AU - Kippenberger, Stefan

PY - 2013/8

Y1 - 2013/8

N2 - Characteristically, most solid tumors exhibit an increased tumor interstitial fluid pressure (TIFP) that directly contributes to the lowered uptake of macromolecular therapeutics into the tumor interstitium. Abnormalities in the tumor-associated lymph vessels are a central brick in the development and prolonged sustaining of an increased TIFP. In the current study, vascular endothelial growth factor C (VEGF-C) was used to enhance tumor-associated lymphangiogenesis as a new mechanism to actively reduce the TIFP by increased lymphatic drainage of the tumor tissue. Human A431 epidermoid vulva carcinoma cells were inoculated in NMRI nu/nu mice to generate a xenograft mouse model. Seven days after tumor cell injection, VEGF-C was peritumorally injected to induce lymphangiogenesis. Tumor growth and TIFP was lowered significantly over time in VEGF-C-treated tumors in comparison to control or VEGF-A-treated animals. These data demonstrate for the first time that actively induced lymphangiogenesis can lower the TIFP in a xenograft tumor model and apparently reduce tumor growth. This model represents a novel approach to modulate biomechanical properties of the tumor interstitium enabling a lowering of TIFP in vivo.

AB - Characteristically, most solid tumors exhibit an increased tumor interstitial fluid pressure (TIFP) that directly contributes to the lowered uptake of macromolecular therapeutics into the tumor interstitium. Abnormalities in the tumor-associated lymph vessels are a central brick in the development and prolonged sustaining of an increased TIFP. In the current study, vascular endothelial growth factor C (VEGF-C) was used to enhance tumor-associated lymphangiogenesis as a new mechanism to actively reduce the TIFP by increased lymphatic drainage of the tumor tissue. Human A431 epidermoid vulva carcinoma cells were inoculated in NMRI nu/nu mice to generate a xenograft mouse model. Seven days after tumor cell injection, VEGF-C was peritumorally injected to induce lymphangiogenesis. Tumor growth and TIFP was lowered significantly over time in VEGF-C-treated tumors in comparison to control or VEGF-A-treated animals. These data demonstrate for the first time that actively induced lymphangiogenesis can lower the TIFP in a xenograft tumor model and apparently reduce tumor growth. This model represents a novel approach to modulate biomechanical properties of the tumor interstitium enabling a lowering of TIFP in vivo.

UR - http://www.scopus.com/inward/record.url?scp=84881048024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881048024&partnerID=8YFLogxK

U2 - 10.1593/tlo.13274

DO - 10.1593/tlo.13274

M3 - Article

VL - 6

SP - 398

EP - 404

JO - Translational Oncology

JF - Translational Oncology

SN - 1936-5233

IS - 4

ER -